Switch to:
Valeant Pharmaceuticals International Inc (NYSE:VRX)
EV/EBITDA
14.79 (As of Today)

EV/EBITDA ratio is calculated as enterprise value divided by its EBITDA. As of today, Valeant Pharmaceuticals International Inc's enterprise value is $63,448 Mil. Valeant Pharmaceuticals International Inc's earnings before depreciation and amortization for the trailing twelve months (TTM) ended in Sep. 2015 was $4,289 Mil. Therefore, Valeant Pharmaceuticals International Inc's EV/EBITDA ratio for today is 14.79.

VRX' s EV/EBITDA Range Over the Past 10 Years
Min: -13.2   Max: 293.5
Current: 20.95

-13.2
293.5

During the past 13 years, the highest EV/EBITDA Ratio of Valeant Pharmaceuticals International Inc was 293.50. The lowest was -13.20. And the median was 16.90.

VRX's EV/EBITDA is ranked lower than
65% of the 821 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.09 vs. VRX: 20.95 )

EV/EBITDA (Enterprise value/EBITDA) is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the P/E Ratio to determine the fair market value of a company.

As of today, Valeant Pharmaceuticals International Inc's stock price is $83.86. Valeant Pharmaceuticals International Inc's earnings per share for the trailing twelve months (TTM) ended in Sep. 2015 was $1.76. Therefore, Valeant Pharmaceuticals International Inc's P/E Ratio for today is 47.65.

The "classic" EV/EBITDA ratio is much better in capturing debt and net cash than the P/E Ratio.


Definition

Valeant Pharmaceuticals International Inc's EV/EBITDA for today is calculated as:

EV/EBITDA=Enterprise Value (Today)/Earnings Before Depreciation and Amortization (TTM)
=63448.471/4288.6
=14.79

Valeant Pharmaceuticals International Inc's current Enterprise Value is $63,448 Mil.
Valeant Pharmaceuticals International Inc's Earnings Before Depreciation and Amortization for the trailing twelve months (TTM) ended in Sep. 2015 was 1304.5 (Dec. 2014 ) + 860.2 (Mar. 2015 ) + 983 (Jun. 2015 ) + 1140.9 (Sep. 2015 ) = $4,289 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

EV/EBITDA (Enterprise value/EBITDA) is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the P/E Ratio to determine the fair market value of a company.

Valeant Pharmaceuticals International Inc's P/E Ratio for today is calculated as:

P/E Ratio=Share Price (Today)/Earnings Per Share (TTM)
=83.86/1.76
=47.65

Valeant Pharmaceuticals International Inc's share price for today is $83.86.
Valeant Pharmaceuticals International Inc's Earnings Per Share for the trailing twelve months (TTM) ended in Sep. 2015 was 1.56 (Dec. 2014 ) + 0.21 (Mar. 2015 ) + -0.15 (Jun. 2015 ) + 0.14 (Sep. 2015 ) = $1.76.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Study has found that the companies with the lowest EV/EBITDA outperforms companies measured as cheap by other ratios such as P/E Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Related Terms

Enterprise Value, Earnings Before Depreciation and Amortization, P/E Ratio


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Valeant Pharmaceuticals International Inc Annual Data

Dec05Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14
ev2ebitda 14.98-10.584.858.579.24225.5430.6632.1160.8826.62

Valeant Pharmaceuticals International Inc Quarterly Data

Jun13Sep13Dec13Mar14Jun14Sep14Dec14Mar15Jun15Sep15
ev2ebitda 30.7454.5060.8853.8239.2324.1126.6237.4837.9231.71
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership

FEEDBACK